Market Research Reports and Industry Reports

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2017

Summary

According to the recently published report GTPase KRas - Pipeline Review, H2 2017; GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

The report GTPase KRas - Pipeline Review, H2 2017 outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 14 and 11 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Metabolic Disorders and Ophthalmology which include indications Pancreatic Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Lung Cancer, Solid Tumor, Actinic (Solar) Keratosis, Basal Cell Carcinoma (Basal Cell Epithelioma), Breast Cancer, Colon Cancer, Corneal Neovascularization, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Macular Degeneration, Osteosarcoma, Prostate Cancer, Small-Cell Lung Cancer and Squamous Cell Carcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
- The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview 8
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 15
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment 17
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type0
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development2
AstraZeneca Plc2
Aurigene Discovery Technologies Ltd2
Boehringer Ingelheim GmbH2
Codiak BioSciences Inc3
Critical Outcome Technologies Inc3
Horizon Discovery Group Plc4
Kyowa Hakko Kirin Co Ltd4
Mirati Therapeutics Inc4
Moderna Therapeutics Inc5
Nuevolution AB5
PeptiDream Inc6
Takeda Pharmaceutical Co Ltd6
Tosk Inc7
Warp Drive Bio Inc7
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles8
ARS-853 - Drug Profile8
Product Description8
Mechanism Of Action8
R&D Progress8
AZD-4785 - Drug Profile9
Product Description9
Mechanism Of Action9
R&D Progress9
Biologics to Inhibit KRAS for Pancreatic Cancer - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
COTI-219 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
HD-001 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
KHK-KRAS - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Krasin-100 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
KRpep-2d - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MM-41 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
mRNA-5671 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SBT-100 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SBT-102 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SBT-200 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
SBT-300 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecule to Inhibit KRAS for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecule to Inhibit KRAS for Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecules to Inhibit K Ras for Oncology - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules to Inhibit KRAS for Non-Small Cell Lung Cancer - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules to Inhibit KRAS for Oncology - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Inhibit KRAS for Oncology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
SML-8731 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Vaccine to Target K-RAS for Lung Cancer - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products 59
GTPase KRas (KRas or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones 60
Featured News & Press Releases 60
Nov 13,017: Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs 60
Dec 16,016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer 60
Oct 11,016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS 61
Aug9,016: FDA Grants Orphan Drug Designation to SBT-100 for Pancreatic Cancer 61
Jul9,014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation 62
May 08,013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement 62
Jan 03,013: Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate For Development, Triggering $5m Milestone Payment To Dicerna Pharma 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indication, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products under Investigation by Universities/Institutes, H2 2017 15
Products under Investigation by Universities/Institutes, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by AstraZeneca Plc, H2 2017 22
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 22
Pipeline by Boehringer Ingelheim GmbH, H2 2017 23
Pipeline by Codiak BioSciences Inc, H2 2017 23
Pipeline by Critical Outcome Technologies Inc, H2 2017 23
Pipeline by Horizon Discovery Group Plc, H2 2017 24
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 24
Pipeline by Mirati Therapeutics Inc, H2 2017 25
Pipeline by Moderna Therapeutics Inc, H2 2017 25
Pipeline by Nuevolution AB, H2 2017 26
Pipeline by PeptiDream Inc, H2 2017 26
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 26
Pipeline by Tosk Inc, H2 2017 27
Pipeline by Warp Drive Bio Inc, H2 2017 27
Dormant Projects, H2 2017 59

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2017

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2017According to the recently published report GTPase KRas - Pipeline

USD 3500View Report

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017According to the recently published report GTPase KRas - Pipeline

USD 3500View Report

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017According to the recently published report GTPase KRas - Pipeline

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Nov 2017
No. of Pages :65
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube